MedTrace Logo

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2015-11-25

Study results available
· View outcomes & findings →

Summary

The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.

Conditions

Interventions

DRUG

tofacitinib ointment 20 mg/g

tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks

DRUG

tofacitinib ointment 10 mg/g

tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks

DRUG

placebo ointment (vehicle)

placebo ointment (vehicle) BID (twice daily) for 12 weeks

DRUG

tofacitinib ointment 20 mg/g

tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks

DRUG

tofacitinib ointment 10 mg/g

tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks

DRUG

placebo ointment (vehicle)

placebo ointment (vehicle) QD (once daily) for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States
  • Canada
  • Denmark
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01831466 on ClinicalTrials.gov